Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...

Inc. (Market cap: $34.46M) has reported its financial performance for the fourth quarter of 2023, highlighting a steady cash flow and strategic advancements in its clinical pipeline. According to ...

After a diagnosis of long COVID, patients in Colorado shifted from seeking care in hospitals and emergency departments (EDs) ...

Tivic Health Systems, Inc., today announced it has acquired worldwide exclusive license rights from Statera Biopharma to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimodtm for the ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...